| Literature DB >> 27290691 |
Martin Sweeney1, Robert Coyle1, Paul Kavanagh1, Andrey A Berezin2, Daniele Lo Re2, Georgia A Zissimou2, Panayiotis A Koutentis2, Michael P Carty3, Fawaz Aldabbagh4.
Abstract
The thioredoxin (Trx)-thioredoxin reductase (TrxR) system plays a key role in maintaining the cellular redox balance with Trx being over-expressed in a number of cancers. Inhibition of TrxR is an important strategy for anti-cancer drug discovery. The natural product pleurotin is a well-known irreversible inhibitor of TrxR. The cytotoxicity data for benzo[1,2,4]triazin-7-ones showed very strong correlation (Pearson correlation coefficients ∼0.8) to pleurotin using National Cancer Institute COMPARE analysis. A new 3-CF3 substituted benzo[1,2,4]triazin-7-one gave submicromolar inhibition of TrxR, although the parent compound 1,3-diphenylbenzo[1,2,4]triazin-7-one was more cytotoxic against cancer cell lines. Benzo[1,2,4]triazin-7-ones exhibited different types of reversible inhibition of TrxR, and cyclic voltammetry showed characteristic quasi-reversible redox processes. Cell viability studies indicated strong dependence of cytotoxicity on substitution at the 6-position of the 1,3-diphenylbenzo[1,2,4]triazin-7-one ring.Entities:
Keywords: Anti-tumor; Bioreduction; Heterocyclic compound; NCI-DTP COMPARE program
Mesh:
Substances:
Year: 2016 PMID: 27290691 DOI: 10.1016/j.bmc.2016.05.066
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641